These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10687260)

  • 21. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
    Goldenberg VK; Seewaldt VL; Scott V; Bean GR; Broadwater G; Fabian C; Kimler B; Zalles C; Lipkus IM
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1032-4. PubMed ID: 17507634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Chemoprevention of breast cancer. Impact of a new therapeutic strategy].
    Kattan J; Ghosn M
    J Med Liban; 1999; 47(5):284-5. PubMed ID: 10887527
    [No Abstract]   [Full Text] [Related]  

  • 23. Chemoprevention research: implications for primary care practice.
    Denicoff AM; Padberg RM
    Lippincotts Prim Care Pract; 2000; 4(4):410-6. PubMed ID: 11261117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug discoveries on the road to preventing breast cancer.
    Capriotti T
    Medsurg Nurs; 1998 Oct; 7(5):304-7. PubMed ID: 10036433
    [No Abstract]   [Full Text] [Related]  

  • 25. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point.
    Jordan VC
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2207-9. PubMed ID: 18006908
    [No Abstract]   [Full Text] [Related]  

  • 26. Women at high risk for breast cancer: preventive strategies.
    Sakorafas GH
    Mt Sinai J Med; 2002 Sep; 69(4):264-6. PubMed ID: 12357269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
    Eeles RA; Powles TJ
    J Clin Oncol; 2000 Nov; 18(21 Suppl):93S-9S. PubMed ID: 11060334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defining the role of raloxifene for the prevention of breast cancer.
    Kalidas M; Hilsenbeck S; Brown P
    J Natl Cancer Inst; 2004 Dec; 96(23):1731-3. PubMed ID: 15572750
    [No Abstract]   [Full Text] [Related]  

  • 29. Methodologic issues in the chemoprevention of breast cancer.
    Cuzick J
    Cancer Detect Prev; 1992; 16(1):81-5. PubMed ID: 1551142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
    Robertson JF
    Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developing phytoestrogens for breast cancer prevention.
    Liu MM; Huang Y; Wang J
    Anticancer Agents Med Chem; 2012 Dec; 12(10):1306-13. PubMed ID: 22583409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tamoxifen: preventing breast cancer and placing the risk of deep vein thrombosis in perspective.
    Goldhaber SZ
    Circulation; 2005 Feb; 111(5):539-41. PubMed ID: 15699272
    [No Abstract]   [Full Text] [Related]  

  • 33. Another view of tamoxifen.
    Napoli M
    Am J Nurs; 2001 Apr; 101(4):33. PubMed ID: 11301681
    [No Abstract]   [Full Text] [Related]  

  • 34. Breast cancer prevention. New options for patients and clinicians.
    Willett LR; August DA; Carson JL
    N J Med; 2002 Sep; 99(9):27-34. PubMed ID: 12244704
    [No Abstract]   [Full Text] [Related]  

  • 35. [Antiestrogens: mechanism of action and clinical applications].
    Barrón-González A; Arias-Martínez J; Castro-Romero I
    Salud Publica Mex; 2001; 43(6):577-84. PubMed ID: 11816234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
    Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
    Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Terpenoids and breast cancer chemoprevention.
    Rabi T; Bishayee A
    Breast Cancer Res Treat; 2009 May; 115(2):223-39. PubMed ID: 18636327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
    Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S
    Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.
    Rondanina G; Puntoni M; Severi G; Varricchio C; Zunino A; Feroce I; Bonanni B; Decensi A
    J Clin Oncol; 2008 Mar; 26(9):1537-43. PubMed ID: 18349406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Chemoprevention of breast cancer: a literature review and report on the current status in Germany].
    Paepke S; V Minckwitz G; Kaufmann M; Schwarz-Boeger U; Jacobs VR; Aigner M; Pfeifer K; Ehmer M; Hüttner C; Blohmer JU; Kiechle M
    Zentralbl Gynakol; 2003 Sep; 125(9):338-45. PubMed ID: 14569515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.